Earnings ·
Veru Inc. reported fiscal third quarter results ending June 30, 2026, with a net loss of $7.0 million ($0.30 per…
VERUVeru Inc.
Veru Inc. reported fiscal third quarter results ending June 30, 2026, with a net loss of $7.0 million ($0.30 per share), compared to a $7.3 million loss in the prior year period. Research and development expenses rose to $4.4 million from $3.0 million, while general and administrative costs fell to $3.4 million from $5.0 million. The company holds $23.9 million in cash as of June 30, 2026. Clinically, the Phase 2b PLATEAU trial for enobosarm combined with semaglutide fully enrolled 239 patients, exceeding its target of 200. Veru secured a clinical supply agreement with Novo Nordisk and received a USPTO notice of allowance for a key patent covering the combination therapy, extending protection until at least October 2044. Interim analysis results are expected in Q1 2027. Veru Inc. is a late-stage biopharmaceutical company developing treatments for cardiometabolic and inflammatory diseases.